Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$2.95 USD

2.95
429,641

+0.10 (3.51%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Do Options Traders Know Something About Puma (PBYI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Puma (PBYI) stock based on the movements in the options market lately.

Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.

Puma Biotech (PBYI) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of -373.91% and -13.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut

by Zacks Equity Research

Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.

Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 58.06% and 4.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View

by Zacks Equity Research

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

Puma Biotech (PBYI) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 37.93% and 31.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celcuity (CELC) Soars on Agreement With Pfizer & Study Data

by Zacks Equity Research

Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.

Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

by Zacks Equity Research

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer

by Zacks Equity Research

Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.

Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

by Zacks Equity Research

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 130.77% and 26.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod

by Zacks Equity Research

Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.

Nilanjan Choudhury headshot

Why the Sell-Off in These 5 Stocks is a Buying Opportunity

by Nilanjan Choudhury

We have zeroed in on five stocks that have witnessed a slump this past week but have a favorable Zacks Rank #1 (Strong Buy) or 2 (Buy).